Characterization of the novel HLA-DPA1*02:15 allele by sequencing-based typing.


Journal

HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570

Informations de publication

Date de publication:
08 2019
Historique:
received: 24 04 2019
revised: 05 05 2019
accepted: 06 05 2019
pubmed: 10 5 2019
medline: 21 5 2020
entrez: 10 5 2019
Statut: ppublish

Résumé

HLA-DPA1*02:15 differs from HLA-DPA1*02:06 by one nucleotide substitution in codon 218 in exon 4.

Identifiants

pubmed: 31070010
doi: 10.1111/tan.13573
doi:

Substances chimiques

Codon 0
HLA-DP alpha-Chains 0
HLA-DPA1 antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

179-180

Informations de copyright

© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Auteurs

Laura Blouin (L)

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.

Marco Andreani (M)

Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy.

Franco Locatelli (F)

Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy.

Gwendaline Guidicelli (G)

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.

Jonathan Visentin (J)

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.
UMR CNRS 5164 Immunoconcept, Université de Bordeaux, Bordeaux, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH